De Novo Pathway Demystified: When to Use It and How to Prepare for FDA Success

What the De Novo Pathway Actually Is—and Why It Matters

If your medical device is genuinely novel—meaning there is no legally marketed predicate device to support a 510(k)—but it also does not pose the level of risk that would require a full Premarket Approval (PMA), you are not in a regulatory dead end. You are a candidate for the De Novo pathway.

Established under Section 513(f)(2) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) and codified through FDA's implementing regulations, the De Novo process allows FDA to classify novel, low-to-moderate risk devices into Class I or Class II—creating a new regulatory classification that did not previously exist. Once granted, your De Novo decision becomes a predicate for future 510(k) submissions from you and your competitors. That is both a strategic advantage and a responsibility to understand fully.

Too many startup founders either default to a 510(k) when no valid predicate exists—setting themselves up for a Not Substantially Equivalent (NSE) determination—or assume they need a PMA and never pursue clearance at all. The De Novo pathway exists precisely to bridge that gap, and underutilizing it is a costly mistake.

De Novo vs. 510(k) vs. PMA: Choosing the Right Lane

Before investing resources in any submission strategy, you need to classify your device correctly. Here is how the three primary pathways differ in practical terms:

• 510(k): Requires demonstration of substantial equivalence to a legally marketed predicate. Best for devices with established technology and a clear predicate chain. FDA review is typically 90 days for Standard, faster for Abbreviated.
• De Novo: Used when no valid predicate exists, but the device presents low-to-moderate risk. Results in a new Class I or Class II classification. FDA's target review time is 150 days under MDUFA V commitments.
• PMA: Required for Class III devices—those where general controls and special controls are insufficient to provide reasonable assurance of safety and effectiveness. Requires valid scientific evidence, typically including clinical trials. Review timelines extend to 180 days or longer.

The critical trigger for De Novo is the absence of a valid predicate. Under 21 CFR 807.100, if FDA issues an NSE decision in response to a 510(k), the sponsor may submit a De Novo request within 30 days of that determination. Alternatively, sponsors can submit a De Novo request directly—without first filing a 510(k)—when the novel nature of the device is already apparent.

When De Novo Is the Right Strategic Choice

The De Novo pathway is appropriate when all of the following conditions are met:

• Your device is new to the U.S. market with no legally marketed predicate under 21 CFR 807.92
• The device technology or intended use creates a new type of risk profile not currently classified by FDA
• Risk is low-to-moderate and can be mitigated through general controls alone (Class I) or general and special controls (Class II)
• You have—or can generate—performance data sufficient to establish special controls for your new classification

Common De Novo candidates include first-of-kind software as a medical device (SaMD) products, novel diagnostic algorithms, combination-technology devices, and hardware with unique indications that fall outside existing classification panels. FDA's guidance document De Novo Classification Process (Evaluation of Automatic Class III Designation), updated in 2021, remains the primary reference document for understanding submission requirements.

How to Build a De Novo Submission That Succeeds

A De Novo request is not simply a 510(k) without a predicate. It requires a fundamentally different evidentiary structure. Here is what FDA expects:

• Device Description: A thorough technical description that clearly articulates what the device does, how it works, and why it is novel. Ambiguity here triggers Additional Information (AI) requests immediately.
• Risk-Based Classification Rationale: You must affirmatively argue why Class II is appropriate—not just assert it. FDA evaluates probable risks and benefits. Reference FDA's guidance on factors to consider when making benefit-risk determinations.
• Proposed Special Controls: This is where many sponsors underinvest. Special controls are the regulatory conditions that will mitigate risk for your device type and all future devices in that classification. They must be specific, enforceable, and technically grounded. Vague special controls will slow your review.
• Performance Data: Bench testing, usability studies, biocompatibility data under ISO 10993, software documentation under IEC 62304 where applicable, and clinical data if risk warrants it. Align your test protocols with recognized FDA consensus standards where possible—use of recognized standards under 21 CFR 820 and FDA's Standards Database simplifies the evidentiary burden.
• Labeling: Draft labeling must reflect the intended use and indications you are seeking. Inconsistencies between labeling and your device description are a common source of AI requests.

Common Pitfalls to Avoid

After reviewing hundreds of regulatory submissions, the failure patterns are consistent. Sponsors underestimate the depth of the special controls section, submit performance data that is not representative of the final device design, or fail to engage FDA through Pre-Submission (Q-Sub) meetings before filing. A Pre-Sub meeting—available under FDA's guidance on the Q-Sub program—is not optional for a De Novo. It is the single highest-leverage activity you can do before committing to a full submission. FDA will tell you whether your classification rationale holds, whether your performance testing is adequate, and whether you are targeting the right pathway.

Missing this step costs sponsors an average of six to twelve months in back-and-forth AI cycles—delays that are entirely avoidable.

The Bottom Line

The De Novo pathway is one of FDA's most powerful—and most misunderstood—regulatory tools. When applied correctly, it clears a first-in-class device, establishes the regulatory framework for an entire product category, and creates a durable market advantage. When approached without preparation, it produces AI requests, extended timelines, and erosion of investor confidence.

At ADB Consulting & CRO Inc., we help medical device companies navigate De Novo strategy from pre-submission through classification order—building submissions that are technically rigorous, strategically sound, and reviewer-ready.

If you are developing a novel device and are unsure whether De Novo is the right pathway, do not guess. Book a free discovery call with Andre Butler and get a clear regulatory roadmap tailored to your device and your timeline. Visit adbccro.com to schedule your call today.